Vistagen Therapeutics’ fast-acting nasal spray drug, fasedienol, hit primary and secondary goals of an abbreviated late-stage study in social anxiety disorder. Vistagen’s stock price rocketed skyward on the results, which support progression to another Phase 3 study.
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.
The consortium will use induced pluripotent stem cell (iPSC) technology — a type of stem cell that can be generated from adult stem cells — to find better treatments for the two psychiatric conditions.
Anxiety disorders are unique to each person who is challenged with them. So why are many patients put in a broad category for treatment?
A new study suggests that there is often a clear genetic link between people who are creative and those who develop a psychiatric disorder.